Abstract
Satavaptan, a vasopressin V2-receptor antagonist, has been shown to improve hyponatraemia in patients with cirrhosis. Hyponatraemia has been associated with an increased risk of hepatic encephalopathy. The objective is to evaluate the efficacy of satavaptan in reducing the risk of new episodes of hepatic encephalopathy. 1,200 patients with cirrhosis and uncomplicated ascites were included in three randomised double-blind studies comparing satavaptan (5–10 mg/day) vs placebo over a one-year treatment period. Effects on incidence of hepatic encephalopathy episodes in individual study and pooled databases were determined with analyses adjusted for hyponatraemia and previous episodes of encephalopathy. Hyponatraemia was improved by satavaptan. Three hundred and ninety-five hepatic encephalopathy episodes were recorded. The risk of an episode and the mean number of episodes were not reduced by satavaptan in any of the three studies in the overall population or in patients who were hyponatraemic on entry. These findings were confirmed in analysis of the pooled data. Satavaptan did not reduce the frequency of hepatic encephalopathy in patients with cirrhosis and ascites.
Similar content being viewed by others
References
Angeli P, Wong F, Watson H, Ginès P, CAPPS investigators (2006) Hyponatraemia in cirrhosis: results of a patient population survey. Hepatology 44:1535–1542
Cardenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH (2012) Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 56:571–578
Cordoba J, Guevara M, Watson HR, Le Guennec S, Ginès P (2009) Improvement of hyponatremia in cirrhosis increases speed of complex information processing. Hepatology 50(4) (suppl):451A
Decaux G, Soupart A, Vassart G (2008) Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371:1624–1632
Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei A (2002) Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35:716–721
Gerbes AL, Gülberg VA, Ginès P, Decaux G, Gross P, Gandjini H, Djian J, VPA study group (2003) Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized, double-blind multicenter trial. Gastroenterology 124:933–939
Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D, HypoCAT Study Investigators (2008) Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48:204–213
Ginès P, Wong F, Watson H, Terg R, Bruha R, Zarski JP, Francis Dudley for the Normocat Study Investigators (2010) Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatremia—a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 31:834–845
Guevara M, Baccaro ME, Torre A, Gómez-Ansón B, Ríos J, Torres F, Rami L, Monté-Rubio GC, Martín-Llahí M, Arroyo V, Ginès P (2009) Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 104:1382–1389
Guevara M, Baccaro ME, Rios J, Martín-Llahí M, Uriz J, Ruiz del Arbol L, Planas R, Monescillo A, Guarner C, Crespo J, Bañares R, Arroyo V, Ginès P (2010) Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int. doi:10.1111/j.1478-3231.2010.02293.x
Restuccia T, Gómez-Ansón B, Guevara M, Alessandria C, Torre A, Alayrach ME, Terra C, Martín M, Castellví M, Rami L, Sainz A, Ginès P, Arroyo V (2004) Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology 39:1613–1622
Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, Attili AF, Merli M (2008) Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol 103:2738–2746
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. New Engl J Med 355:2099–2112
Wong F, Ginès P, Watson H, Horsmans Y, Angeli P, Gow P, Minini P, Bernardi M (2010) Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 53:283–290
Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, Ginès P (2012) Satavaptan for the management of ascites in cirrhosis; efficacy and safety across the spectrum of ascites severity. Gut 61:108–116
Acknowledgments
The authors thank the clinical investigators of the CATS, SPARe-1 and SPARe-2 studies for their participation and Pascal Minini for statistical analysis. The study was supported by Sanofi Research and Development.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Watson, H., Jepsen, P., Wong, F. et al. Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. Metab Brain Dis 28, 301–305 (2013). https://doi.org/10.1007/s11011-013-9384-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-013-9384-4